1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Charting The Slow-Growing Psoriatic Arthritis Market

 
• By Emily Hayes

Market Snapshot: Despite the availability of anti-TNF biosimilars, the global market for drugs for psoriatic arthritis will grow to $4.1bn in 2025 due to the entry of new branded drugs at high prices in the US, according to a new Datamonitor Healthcare forecast report.

snail showing slow growth

The US FDA's recent approvals of Pfizer Inc.'s JAK inhibitor Xeljanz, Eli Lilly & Co.'s IL-17A inhibitor Taltz and Johnson & Johnson's infused anti-TNF Simponi Aria for psoriatic arthritis brings three more products into a crowded space already dominated by mainstay TNF blockers, which are beginning to face biosimilars competition.

The FDA approved a new indication on Dec. 14 for Xeljanz (tofacitinib), given orally twice daily or in a once-daily formulation (Xeljanz XR) for patients with active psoriatic arthritis (PsA)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

More from Therapy Areas

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.